glp-1 antagonists receptor agonists show promise in treating substance use disorders America's Poison Centers - GLP-1
Description
A post-hoc analysis of STEP 1, 2, 3, and 5 found a small but statistically significant reduction in depressive symptoms with semaglutide compared to placebo
The influence of SGLT2 inhibitors, dipeptidyl peptidase IV (DPP-4) inhibitors, and sulfonylureas on cancer risk remains inconclusive
Ethics declarations Competing interests D.H., C.M.R., L.J., J.F., and J.G
Others require continued 12mg dosing to prevent regain
Glucagon-like peptide-1 receptor agonists (GLP-1 RAs) and suicidality: a replication study using reports to the World Health Organization pharmacovigilance database (VigiBase)
In certain cases, specific medications may be considered
